共 50 条
- [31] Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitisJOURNAL OF CROHNS & COLITIS, 2024, 18 : I437 - I438Kong, K. F.Khan, M. A. W.Singh, N.Nguyen, V. A.Wilson, E.Tang, J.Marusic, S.Xia, G.Petrakis, I.Nguyen, D. G.
- [32] An oral, selective tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, improves quality of life (QoL) in psoriasis (PsO): results from a Phase 2 studyJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 24 - 25Thaci, DiamantPapp, Kim AlexanderGordon, KennethMorita, AkimichiGooderham, MelindaFoley, PeterAlemao, EvoKisa, RenataElbez, YedidRen, HaoboBanerjee, Subhashis
- [33] DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUSANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1506 - 1506Werth, V. P.Merola, J. F.Wenzel, J.Delev, N.Kothari, H.Meier, R.Singhal, S.Madireddi, M.Korish, S.
- [34] Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling PathwaysFRONTIERS IN IMMUNOLOGY, 2022, 13Zhou, YuLi, XinShen, RuWang, XiangzhuZhang, FanLiu, SuxingLi, DiLiu, JianLi, PuhuiYan, YinfaDong, PingZhang, ZhigaoWu, HepingZhuang, LinghangChowdhury, RasheduzzamanMiller, MatthewIssa, MenaMao, YuchangChen, HongliFeng, JunLi, JingBai, ChangHe, FengTao, Weikang
- [35] Discovery of the TYK2 selective inhibitor PF-6826647 for the treatment of Crohn's disease, and other autoimmune conditionsABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256Gerstenberger, BrianArnold, EricBanker, Mary EllenBrown, MatthewClark, JamesDermenci, AlpayDowty, MartinFensome, AndrewHayward, MatthewHegen, MartinHollingshead, BrettKnafels, JohnLin, DavidLin, TsungOwen, DafyddSaiah, EddineSharma, RamanVajdos, FelixVincent, FabienWright, StephenXing, LiYang, XiaojingYang, XinZhang, Liying
- [36] Identification of highly potent and selective Tyk2 inhibitors for the treatment of autoimmune diseases through structure-based drug designJOURNAL OF IMMUNOLOGY, 2015, 194Masse, CraigMiao, WenyanGreenwood, JeremyShelley, MeeKennedy-Smith, JoshuaKapeller, Rosana
- [37] MODULATION OF DISEASE-CENTRAL CYTOKINE PATHWAYS WITH TAK-279, A HIGHLY SELECTIVE ORAL TYK2 INHIBITOR, DEFINES CLINICAL RESPONSE IN PATIENTS WITH PSORIASISACTA DERMATO-VENEREOLOGICA, 2024, 104Choudhury, AmitGarcet, SandraCheng, JieKumar, SachinTang, JayBlau, JessamynZhao, YiweiZhang, WenwenSaha, BanishreeArunachalam, VinuHeap, Graham A.Thakker, PareshKrueger, James
- [38] Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, modulates disease-central cytokine pathways that define clinical response in patients with moderate-to-severe plaque psoriasisBRITISH JOURNAL OF DERMATOLOGY, 2024, 191Krueger, James G.Garcet, SandraCheng, JieKumar, SachinTang, JayBlau, JessamynZhang, WenwenSaha, BanishreeArunachalam, VinayagamHeap, Graham A.Winkelman, WarrenThakker, PareshChoudhury, Amit
- [39] Exposure-Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal SymptomsARTHRITIS & RHEUMATOLOGY, 2019, 71Shen, JunChimalakonda, AnjaneyaNowak, MiroslawaThroup, JohnBanerjee, SubhashisGirgis, Ihab
- [40] Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis TrialDERMATOLOGY AND THERAPY, 2024, 14 (10) : 2827 - 2839Catlett, Ian M.Gao, LuHu, YanhuaBanerjee, SubhashisKrueger, James G.